House Energy and Commerce hearing spotlights Medicare coverage for multicancer early‑detection tests

At a House Energy and Commerce subcommittee hearing, members and witnesses debated H.R. 842, the Nancy Gardner Sewell Medicare Multicancer Early Detection Screening Coverage Act, which would give the Centers for Medicare & Medicaid Services (CMS) an authority-based pathway to evaluate whether to cover FDA‑authorized blood-based multicancer early detection tests for Medicare beneficiaries.

The bill’s supporters said the tests, which analyze circulating tumor DNA from a blood draw, could detect many cancers earlier than current, organ‑specific screening programs and therefore save lives and money. Steven Ezell, vice president of global innovation policy at the Information Technology and Innovation Foundation, said, “Cancer claims over 600,000 American lives annually,” and argued that MCED tests can expand screening beyond the five cancers now commonly screened for.

Why it matters: Seniors account for most U.S. cancer diagnoses and cancer care consumes substantial Medicare dollars; lawmakers said a coverage pathway could increase timely access if FDA authorizations demonstrate clinical value. Patient testimony underscored that point. Roger Royce, a patient advocate who described being diagnosed after a liquid‑biopsy MCED test, told the subcommittee, “I only caught this through multicancer early detection. This is something that saves lives.”

What witnesses said: Todd Brinton, corporate vice president and chief scientific officer for advanced technologies at Edwards Lifesciences, described the broader problem of coverage lag after FDA authorization and said “transitional coverage policies offer a promising bridge” so patients can access therapies while additional evidence is developed. Mr. Ezell and other supporters said the bill would not mandate coverage but would create an evidence‑based process for CMS to consider coverage of FDA‑approved MCED tests.

Cautions and evidence questions: Diana Zuckerman, Ph.D., president of the National Center for Health Research, said MCED tests are “so promising, but they’re not quite ready for prime time yet,” pointing to limited clinical trial data, possible bias in studies, and concerns about false positives and false negatives. David Lipschutz, co‑director of the Center for Medicare Advocacy, expressed concern about an age‑based phase‑in included in the draft text, saying the proposal’s “arbitrary age cutoff … is based solely on cost rather than clinical consideration,” and that Medicare coverage decisions should be equitable across the Medicare population.

Policy design details discussed: Witnesses and members noted that current MCED candidates generally use genomic sequencing and machine learning to search for tumor DNA; panels described tests that screen for as many as “over 50 different types of cancers.” Proponents urged that any CMS pathway should: (1) rely on FDA authorization as a trigger for CMS review; (2) use an evidence‑based assessment of “reasonable and necessary” for Medicare patients; and (3) include clear communication about test performance, including false positive and false negative risks.

Context and concerns raised by members: Ranking Member Diana DeGette and others framed the MCED discussion alongside broader concerns about federal research funding and the pipeline of cancer therapeutics. Several members pressed witnesses on how to avoid overdiagnosis and on the need for additional trials that include older adults, who are the principal Medicare population.

Next steps: The subcommittee took testimony for the record and invited further written questions; no vote occurred at the hearing. Members said they expect to continue refining the statutory language and to consider stakeholder input on evidence standards, eligibility criteria, and implementation logistics.

Ending note: Proponents and skeptics agreed on one point during the hearing: earlier detection can change outcomes for individual patients, and the committee’s decisions will shape how and when Medicare beneficiaries can access emerging MCED technologies.